Join the COVonco study and help understand the impact of COVID-19 in oncology
Collaborate with us!
This study has a multicentric approach. Those interested in participating in the research can contact the Study Coordinator directly.
Why study COVID-19 in cancer patients?
Cancer patients seem to be particularly susceptible to morbilities and mortality by this disease (1,2,3). Moreover, the first studies in cancer patients suggested an increase in the risk to get this viral infection and develop complications related to COVID-19 (4,5,6,7,8). It should also be taken into consideration that several studies remark the high mortality by COVID-19 in cancer patients (8,9,10).
How can this study be useful?
This study aims to establish preventive strategies in oncologic patients, especially in the case of receiving immunosuppressive chemotherapy. The results could be useful to help doctors in informed debates about the risk of COVID-19 and allow a focus based on evidence of national policies of social isolation.
Description of the Study:
- Title: Diagnosis and serologic follow-up of COVID-19 in oncologic patients (COVonco).
- Principal Investigator: Cristina Royo-Cebrecos.
- Co-Investigators: Irene Ambatlle, Ïa Montaner, Eva Mahía, Jaume Pujadas Francesc Cobo, Santiago Albiol.
- Centers of Implementation: the pilot center will be the Servei Andorrà de Salut Sanitària (SAAS). This study is open to collaborations from other centers.
- Study Population: adult patients with an oncologic disease under follow-up by the Service of Oncology or Haematology in a 5-year period (2016-2020) that have a serological test for SARS-CoV-2. From these patients, a subgroup of patients with active oncological treatment will be selected.
- Study Type: observational, cohort, multicentric, prospective study.
Objetives of the Study:
- Principal Objective: Compare the prevalence of SARS-CoV-2 between groups of the oncologic population depending on the type of treatment: chemotherapy, immunotherapy, radiotherapy, and oncologic population without active treatment.
- Secondary Objectives:
(1) Assess the serologic response over time in a follow-up period of 3, 6, and 12 months.
(2) Identify the incidence of asymptomatic infection in the oncologic population and detection of seroconversion.
(3) Estimate the percentages of active infection (positive PCR) among cancer patients with a positive IgM test.
(4) Estimate the global seroprevalence of SARS-CoV-2 of cancer patients.
(5) Identify the diagnostic follow-up of SARS-CoV-2 of cancer patients.
(6) Identify how the management of the oncologic disease changes in case of a positive diagnosis of SARS-CoV-2.